<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20894">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834884</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1553</org_study_id>
    <nct_id>NCT02834884</nct_id>
  </id_info>
  <brief_title>SPECTArare: Screening Patients With Rare Tumors for Efficient Clinical Trial Access</brief_title>
  <acronym>SPECTArare</acronym>
  <official_title>SPECTArare: Screening Patients With Rare Tumors for Efficient Clinical Trial Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPECTArare is a program aiming at establishing a quality assured platform for collecting
      clinicopathologically annotated biological material from patients with primary rare tumors
      (6 new cases/100,000/year) to support biospecimen-based translational research and biomarker
      discovery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of patients with rare tumors enrolled in the program</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adequate material for molecular analysis and correlative clinic-pathological data</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of downstream research projects and clinical trials</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Rare Tumors (Annual Incidence &lt;6/100000)</condition>
  <arm_group>
    <arm_group_label>Rare tumours</arm_group_label>
    <description>Any rare tumor types, as defined by the RARECARE working group (http://www.rarecarenet.eu/), i.e. tumors with annual incidence of less than 6 new cases per 100000 persons, at any stage</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Tumour markers testing</intervention_name>
    <arm_group_label>Rare tumours</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FFPE tissue sample Blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pathologically confirmed rare tumor types, as defined by the RARECARE
        working group (http://www.rarecarenet.eu/), i.e. tumors with annual incidence of less than
        6 new cases per 100000 persons.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathologically confirmed rare tumor types

          -  Mandatory availability of adequate human biological material (HBM): at least one FFPE
             tissue sample from either the primary tumor and/or recurrent tumor and/or metastasis,
             obtained from any adequate surgery or biopsy

          -  Centrally performed confirmation of tumor tissue adequacy in terms of quality/
             quantity for central screening;

          -  Minimal dataset of demographic, clinicopathological and treatment data to be
             recorded;

          -  Age â‰¥ 16 years;

          -  Written informed consent according to ICH/GCP and national/local regulations;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassilis Golfinopoulos, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>European Organisation for Research and Treatment of Cancer - EORTC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina Verschuere, MSc</last_name>
    <phone>+32 2 774 1504</phone>
    <email>tina.verschuere@eortc.be</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 2, 2017</lastchanged_date>
  <firstreceived_date>July 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rare cancer</keyword>
  <keyword>biomarker</keyword>
  <keyword>screening</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
